T1	CHEM 13 28	insulina lispro
#1	AnnotatorNotes T1	C0293359; insulin lispro; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Hormone
T2	CHEM 43 60	insulina glargina
#2	AnnotatorNotes T2	C0907402; insulin glargine; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Hormone
T3	DISO 69 84	diabetes tipo 2
#3	AnnotatorNotes T3	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T4	CHEM 133 141	insulina
#4	AnnotatorNotes T4	C0021641; Insulin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance | C3537244; Insulins; Pharmacologic Substance
T5	DISO 173 188	diabetes tipo 2
#5	AnnotatorNotes T5	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T6	CHEM 269 284	insulina lispro
#6	AnnotatorNotes T6	C0293359; insulin lispro; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Hormone
T7	CHEM 301 318	insulina glargina
#7	AnnotatorNotes T7	C0907402; insulin glargine; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Hormone
T8	PROC 573 586	aleatorizados
#8	AnnotatorNotes T8	C0034656; Randomization; Research Activity
T10	CHEM 530 564	medicaciones orales antidiabéticas
#9	AnnotatorNotes T10	C0359086; oral hypoglycemics; Pharmacologic Substance
T11	CHEM 605 620	insulina lispro
#10	AnnotatorNotes T11	C0293359; insulin lispro; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Hormone
T12	CHEM 629 654	insulina lispro protamina
#11	AnnotatorNotes T12	C0982221; insulin lispro protamine, human; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Hormone
T13	CHEM 691 708	insulina glargina
#12	AnnotatorNotes T13	C0907402; insulin glargine; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Hormone
T14	PROC 882 887	HbA1c
#13	AnnotatorNotes T14	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T15	PROC 939 962	automonitoreo glucémico
T16	DISO 976 988	hipoglucemia
#14	AnnotatorNotes T16	C0020615; Hypoglycemia; Disease or Syndrome
T17	PROC 1300 1302	GA
#15	AnnotatorNotes T17	C0202045; Glucose measurement, fasting; Laboratory Procedure | C0428568; Fasting blood glucose measurement; Laboratory Procedure
T18	DISO 1541 1553	hipoglucemia
#16	AnnotatorNotes T18	C0020615; Hypoglycemia; Disease or Syndrome
T19	DISO 1571 1587	eventos adversos
#17	AnnotatorNotes T19	C0877248; Adverse event; Pathologic Function
T20	DISO 1659 1671	hipoglucemia
#18	AnnotatorNotes T20	C0020615; Hypoglycemia; Disease or Syndrome
T21	Observation 1688 1703	aumento de peso
#19	AnnotatorNotes T21	C0043094; Weight Gain; Finding
T22	PROC 1 8	Régimen
#20	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	DISO 190 193	DT2
#21	AnnotatorNotes T23	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T24	PROC 209 240	Se comparó eficacia y seguridad
#22	AnnotatorNotes T24	C0511730; Identify product efficacy and safety issues; Health Care Activity
T25	PROC 120 141	regímenes de insulina
#23	AnnotatorNotes T25	C0557978; Insulin regime; Therapeutic or Preventive Procedure
T26	PROC 362 370	tratados
#24	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	PROC 248 257	regímenes
#25	AnnotatorNotes T27	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T28	DISO 476 479	DT2
#26	AnnotatorNotes T28	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T29	Observation 1403 1428	aumento del peso corporal
#27	AnnotatorNotes T29	C0043094; Weight Gain; Finding
T30	CHEM 387 395	insulina
#28	AnnotatorNotes T30	C0021641; Insulin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance | C3537244; Insulins; Pharmacologic Substance
T31	PROC 508 513	HbA1c
#29	AnnotatorNotes T31	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T32	Observation 903 926	cambio en peso corporal
#30	AnnotatorNotes T32	C0005911; Body Weight Changes; Finding
T33	PROC 1119 1124	HbA1c
#31	AnnotatorNotes T33	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T34	PROC 785 790	HbA1c
#32	AnnotatorNotes T34	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T35	ANAT 918 926	corporal
#33	AnnotatorNotes T35	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T36	PROC 1027 1032	HbA1c
#34	AnnotatorNotes T36	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T37	PROC 1145 1164	niveles de glucemia
#35	AnnotatorNotes T37	C0392201; Blood glucose measurement; Laboratory Procedure
T38	PROC 1280 1298	glucemia en ayunas
#36	AnnotatorNotes T38	C0202045; Glucose measurement, fasting; Laboratory Procedure | C0428568; Fasting blood glucose measurement; Laboratory Procedure
T39	ANAT 1420 1428	corporal
#37	AnnotatorNotes T39	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T40	CHEM 1640 1647	glucosa
#38	AnnotatorNotes T40	C0017725; glucose; Organic Chemical · Biologically Active Substance · Pharmacologic Substance
T41	LIVB 349 358	pacientes
#39	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	Neg_cue 359 361	no
T43	Duration 425 435	24 semanas
T44	Age 464 474	30-79 años
T45	Route 543 549	orales
#40	AnnotatorNotes T45	C1527415; Oral Route of Drug administration; Functional Concept
T46	Form 658 668	suspensión
#41	AnnotatorNotes T46	C4724031; Suspension Dosage Form; Biomedical or Dental Material
T47	Frequency 670 683	dos veces/día
T48	Duration 793 807	las 24 semanas
T49	LIVB 857 866	pacientes
#42	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group
T50	LIVB 1098 1107	pacientes
#43	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Time 1185 1193	desayuno
#44	AnnotatorNotes T51	C1550743; After Breakfast; Temporal Concept
T52	Time 1214 1218	cena
#45	AnnotatorNotes T52	C0585040; Evening meal; Temporal Concept
T53	Time 1236 1246	las 3 a.m.
T54	LIVB 1323 1332	pacientes
#46	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T56	Neg_cue 1568 1570	ni
T58	Spec_cue 1649 1658	riesgo de
T59	LIVB 145 156	poblaciones
#47	AnnotatorNotes T59	C1257890; Population; Population Group
T60	Dose 598 601	25%
T61	Dose 622 625	75%
T62	Frequency 716 728	una vez/ día
T9	PROC 1352 1357	HbA1c
#48	AnnotatorNotes T9	C0202054; Glucohemoglobin measurement; Laboratory Procedure
A1	Assertion T26 Negated
A2	Assertion T19 Negated
A3	Assertion T20 Speculated
A4	Status T26 History_of
A5	Status T30 History_of
A6	Assertion T30 Negated
R1	Negation Arg1:T56 Arg2:T19	
R2	Speculation Arg1:T58 Arg2:T20	
R3	Negation Arg1:T42 Arg2:T26	
T55	Neg_cue 1503 1505	No
T57	CONC 1515 1526	diferencias
A7	Assertion T57 Negated
#49	AnnotatorNotes T57	C1705241; Delta (difference); Quantitative Concept
R4	Negation Arg1:T55 Arg2:T57	
R5	Used_for Arg1:T1 Arg2:T22	
R6	Used_for Arg1:T2 Arg2:T22	
R7	Used_for Arg1:T4 Arg2:T25	
R8	Experiences Arg1:T59 Arg2:T25	
R9	Experiences Arg1:T59 Arg2:T5	
R10	Experiences Arg1:T59 Arg2:T23	
R11	Used_for Arg1:T6 Arg2:T27	
R12	Used_for Arg1:T7 Arg2:T27	
T63	Quantifier_or_Qualifier 319 324	basal
#50	AnnotatorNotes T63	C1442488; Baseline; Quantitative Concept
R13	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T63	
R14	Used_for Arg1:T30 Arg2:T26	
R15	Negation Arg1:T42 Arg2:T30	
R16	Experiences Arg1:T41 Arg2:T26	
R17	Experiences Arg1:T41 Arg2:T30	
R18	Has_Age Arg1:T41 Arg2:T44	
T64	CONC 411 421;436 446	iniciación del ensayo
#51	AnnotatorNotes T64	C4684789; Study Start; Temporal Concept
R19	Has_Duration_or_Interval Arg1:T64 Arg2:T43	
R20	Experiences Arg1:T41 Arg2:T28	
T65	Quantifier_or_Qualifier 480 506	controlada inadecuadamente
R21	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T65	
T66	Result_or_Value 514 520	> 7.0%
R22	Has_Result_or_Value Arg1:T31 Arg2:T66	
R23	Experiences Arg1:T41 Arg2:T31	
T67	Quantifier_or_Qualifier 526 529	= 2
R24	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T67	
R25	Has_Route_or_Mode Arg1:T10 Arg2:T45	
R26	Experiences Arg1:T41 Arg2:T10	
R27	Before Arg1:T8 Arg2:T11	
R28	Before Arg1:T8 Arg2:T13	
R29	Has_Drug_Form Arg1:T12 Arg2:T46	
R30	Has_Dose_or_Strength Arg1:T12 Arg2:T61	
R31	Has_Dose_or_Strength Arg1:T11 Arg2:T60	
R32	Combined_with Arg1:T11 Arg2:T12	
R33	Experiences Arg1:T41 Arg2:T11	
R34	Before Arg1:T10 Arg2:T8	
R35	Has_Frequency Arg1:T11 Arg2:T47	
R36	Has_Frequency Arg1:T12 Arg2:T47	
R37	Has_Frequency Arg1:T13 Arg2:T62	
T68	Quantifier_or_Qualifier 709 714	basal
#52	AnnotatorNotes T68	C1442488; Baseline; Quantitative Concept
R38	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T68	
R39	Experiences Arg1:T41 Arg2:T13	
R40	Overlap Arg1:T34 Arg2:T48	
R41	Experiences Arg1:T49 Arg2:T14	
R42	Location_of Arg1:T35 Arg2:T32	
R43	Experiences Arg1:T49 Arg2:T32	
R44	Experiences Arg1:T49 Arg2:T15	
R45	Experiences Arg1:T49 Arg2:T16	
T69	Observation 1011 1032	reducción de la HbA1c
#53	AnnotatorNotes T69	C0855304; Glycosylated haemoglobin decreased; Finding
R47	Experiences Arg1:T50 Arg2:T33	
R48	Experiences Arg1:T50 Arg2:T69	
R49	Experiences Arg1:T50 Arg2:T36	
R50	Experiences Arg1:T50 Arg2:T37	
R51	After Arg1:T37 Arg2:T51	
R52	After Arg1:T37 Arg2:T52	
R53	Overlap Arg1:T37 Arg2:T53	
R54	Experiences Arg1:T54 Arg2:T9	
R55	Experiences Arg1:T54 Arg2:T38	
R56	Experiences Arg1:T54 Arg2:T17	
R57	Location_of Arg1:T39 Arg2:T29	
R58	Overlap Arg1:T26 Arg2:T64	
R59	Overlap Arg1:T64 Arg2:T28	
R60	Overlap Arg1:T64 Arg2:T31	
R61	Overlap Arg1:T64 Arg2:T10	
R62	Overlap Arg1:T64 Arg2:T8	
R63	Overlap Arg1:T64 Arg2:T11	
R64	Overlap Arg1:T64 Arg2:T12	
R65	Overlap Arg1:T64 Arg2:T13	
R46	After Arg1:T33 Arg2:T51	
R66	After Arg1:T33 Arg2:T52	
R67	Overlap Arg1:T33 Arg2:T53	
#54	AnnotatorNotes T15	C0005803; Blood Glucose Self-Monitoring; Diagnostic Procedure
A8	Experiencer T50 Patient
A9	Experiencer T54 Patient
A10	Experiencer T59 Patient
A11	Experiencer T41 Patient
A12	Experiencer T49 Patient
R68	Has_Result_or_Value Arg1:T36 Arg2:T69	
